This contract supports the prevent cancer preclinical drug development program, which provides a structured approach to drug and vaccine development, from discovery to the clinic. This contract is a…
Ended Awarded Last action
- Contract number
- 75N91019D00018
- Awardee
-
Southern Research Institute UEI CDZJAJJHJMH5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 1 $6,669 obligated
Award facts
- Opportunity
-
- PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarker Endpoints, Preclinical Services for Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing Pre-Solicitation · N01CN7701918 · Posted Apr 19, 2018
- PREVENT Cancer Preclinical Drug Development Program Award Notice · Posted May 7, 2018
- Combined order value
- $6,669 Current and potential, with all options
- Last date to order 100% complete
- IDV ceiling <1% used
- $74,995,000.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Description
This contract supports the prevent cancer preclinical drug development program, which provides a structured approach to drug and vaccine development, from discovery to the clinic. This contract is a part of a multiple-award indefinite delivery indefinite quantity (IDIQ) pool to procure services related to toxicology and pharmacology testing, which is referred to as the toxicology pool.
Task orders
| Task order | Ordering agency | Obligated | Awarded |
|---|---|---|---|
| Contract orientation and kick-off meeting | National Cancer Institute (NIH) | $6,669 |
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Additional Work (new agreement, FAR part 6 applies) | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N91019D00018?
75N91019D00018 was awarded to Southern Research Institute by National Cancer Institute (National Institutes of Health) on January 24, 2019.
How much is contract 75N91019D00018 worth?
Orders under 75N91019D00018 have obligated $6,669. 75N91019D00018's own ceiling is $74,995,000.
How many orders have been placed under contract 75N91019D00018?
1 order has been placed under 75N91019D00018, the latest on January 25, 2019.
Who can order from contract 75N91019D00018?
75N91019D00018 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract 75N91019D00018 part of a contract vehicle?
Yes. 75N91019D00018 is part of PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91019D00018 competed?
The extent of competition for 75N91019D00018 was full and open competition. The government received 4 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV